UPDATE: Alexion Pharma (ALXN) Reports Q2 Revenue of $753M; Trims FY16 Outlook

(Updated - July 28, 2016 7:06 AM EDT)

(Update notes EPS figure does not compare with consensus)

Alexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $1.13, does not compare with the analyst estimate of $1.18.

(Note: Non-GAAP diluted EPS for the second quarter 2016 was $1.13 per share, reflecting a reduction of $0.12 per share attributable to the modification of reported non-GAAP income tax expense; prior to this modification non-GAAP diluted EPS would have been reported at $1.25 per share (Table 2). Non-GAAP diluted EPS was $1.30 per share in the second quarter 2015, reflecting a reduction of $0.14 per share attributable to the tax modification.)

Revenue for the quarter came in at $753 million versus the consensus estimate of $743.18 million.

GUIDANCE:

Alexion Pharma sees FY2016 EPS of $4.50-$4.65, versus prior guidance of $5.00-$5.20.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Range Resources (RRC) Tops Q1 EPS by 11c; offers production guidance
• KKR Real Estate Finance Trust (KREF) Tops Q1 EPS by 4c